I have covered Tarsus Pharmaceuticals ( TARS ) several times, highlighting the company as a Buy due to the robust growth of Xdemvy. Since my first article one year ago, the stock has risen from $47 to $75, a 60% gainBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee a ...

If an American Blue-Chip stock had dropped 40% in six months, you would have most likely read headlines about it and been tempted to enter just for the sake of paying less than half a year ago. With NintendoExcellent academic Finance background and Finance professional with over five years of cumulative experience in Consulting & Audit Firms including a professional Valuation position, FP&A and Controlling positions, and Financial writing.My approach is mostly value-oriented. However, valuation is rarely an ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.3, delivering a surprise of +14.29%.Over the last four quarters, the company ...

Tarsus Pharmaceuticals (NasdaqGS:TARS) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnthea Li - Senior Associate in Biotechnology Equity ResearchBobak Azamían - CEO and ChairmanDavid Nakasone - Head of Investor RelationsGraig Suvannavejh - Biotechnology Small & Midcap and Pharmaceuticals SpecialtyJeffrey Farrow - CFO and Chief Strategy OfficerJena Davidner - Vice President of Equity ResearchMatthew Caufield - Vice President of Equity ResearchSeshadri Neervannan - COOConference Cal ...

Tarsus Pharmaceuticals (NasdaqGS:TARS) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnthea Li - Senior Associate in Biotechnology Equity ResearchBobak Azamían - CEO and ChairmanDavid Nakasone - Head of Investor RelationsGraig Suvannavejh - Biotechnology Small & Midcap and Pharmaceuticals SpecialtyJeffrey Farrow - CFO and Chief Strategy OfficerJena Davidner - Vice President of Equity ResearchMatthew Caufield - Vice President of Equity ResearchSeshadri Neervannan - COOConference Cal ...

Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales at $151.7 million and a gross-to-net discount of 44% [3][20] - Total operating expenses for 2025 were $522.3 million, primarily due to commercial investments for the XDEMVY launch [20] - The company ended 2025 with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [20] Business Line Data and Key Metrics Changes - XDEMVY, the FDA-approved therapeutic for Demodex blepharitis, has helped over 500,000 patients since its launch and is expected to reach blockbuster status with sales potential exceeding $2 billion [3][4] - The company plans to expand its pipeline with two clinical-stage programs: TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, targeting one to two new programs per year [4][5] Market Data and Key Metrics Changes - The U.S. market for Demodex blepharitis is estimated to have 25 million affected individuals, with significant growth potential as awareness and treatment options expand [7][8] - Tarsus has achieved over 90% coverage across commercial Medicare and Medicaid, enhancing patient access [9] Company Strategy and Development Direction - Tarsus aims to create and lead new categories in eye care by identifying diseases with clear root causes and unmet needs, applying the successful development and commercial playbook established with XDEMVY [4][5] - The company is focused on disciplined growth, leveraging existing infrastructure while responsibly allocating capital to extend its long-term growth trajectory [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [7][34] - The company anticipates strong net product sales guidance for 2026 in the range of $670 million to $700 million, representing over 50% growth at the midpoint [21][22] Other Important Information - Tarsus is preparing for the Phase 2 trial of TP-04, expected to cost between $7 million and $10 million, and the Phase 2 trial of TP-05, estimated at $25 million to $30 million [25][72] - The company is also making progress with TP-03 for potential regulatory approval in Europe and Japan, with expectations for approval in China later this year [19] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $370 million-$400 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [31][32] Question: What is driving the increased conviction for the $2 billion peak sales target? - The increase is attributed to the broadening prescriber base and deeper engagement with top-tier prescribers, alongside continued flawless execution in commercial efforts [40][41] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [45][46] Question: What are the expected costs for the ocular rosacea and Lyme disease studies? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost $25 million to $30 million [72]

Building the Future of Eye Care Q4 & Full Year 2025 Financial Results February 2026 Vivian, an XDEMVY patient. World-Class Leadership Team With Proven Track Record of Success 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Sesha Neervannan, PhD Chief Operating Officer Jeff Farrow Chief Financial & Strategy Officer Forward-looking Statements This presentation contains forward-looking statements that involve risks and unce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other ju ...

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements Generated full-year 2025 net product sales of XDEMVY of $451.4 million, an increase of more than 150% year-over-year ® Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference ca ...

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWS ...